Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 06, 2017 | September 08, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 06, 2017 · Filed September 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 914 |
Reported balance
After 2017-09-06 transaction · row 1
1 source rowRow 1 · 2017-09-06 · Sale · Disposed 1,059 · Balance 914 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.72 to $121.728, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.19 · Expires 2026-10-26 | Direct | 3,985 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,985 F2: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.78 · Expires 2024-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.39 · Expires 2023-10-30 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.34 · Expires 2025-10-28 | Direct | 4,260 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,260 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.35 · Expires 2021-10-26 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.90 · Expires 2022-10-24 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.47 · Expires 2018-10-22 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.03 · Expires 2019-10-28 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 5,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.46 · Expires 2020-10-27 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-09-06 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.72 to $121.728, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2017 Filed Sep 8, 2017 20:44 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,059 | $121.73 | $128,909.10 |
DisclosureSEC source: 0001562180-17-002919 · primarydocument.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.72 to $121.728, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · derivative · entry 3 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $111.15 | $555,773.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · nonDerivative · entry 2 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.355, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $66.59 | $332,950.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,000 | $106.73 | $106,733.00 |
DisclosureSEC source: 0000914190-16-000915 · edgar.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $106.90 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000859 · edgar.xml · derivative · entry 2 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000859 · edgar.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.